logo
Misela Opens First Manhattan Store In Noho

Misela Opens First Manhattan Store In Noho

Forbes15-05-2025
Inside the new Misela store
By now New York City Mayor Eric Adams is infamously known as a big fan of Turkey's but it also seems Turkey is a fan of the Big Apple. At least when it comes to luxury accessories. Two brands, Misela and Serena Uziyel have both opened retail spaces in the past month as their customer base expands. It also points to the ongoing larger trend of brands focusing on DTC in their own retail spaces whose locations are easily determined based on online data.
For Misela, founded by Serra Türker Bayr, the downtown cool of Bond Street beckoned. The brand's roots began in New York when Türker Bayr, launched Misela in 2008 with a largely wholesale business model. The brand, whose names refers to the first two letters of Serra and her sisters name, is produced in Turkey and hit the market during the indie accessories boom and garnered prestigious industry recognition, selling at Henri Bendel and Scoop in their heyday. As the brand grew, so did Serra's as she got married and started a family, she eventually returned to Turkey full time.
The Anatolia chevron style is a customizable bag in a variety of styles
By 2012 she had opened her first store in Istanbul. 'We started growing the brand there slowly, shifting from wholesale to DTC. The brand got bigger so along the way I wanted to expand internationally, and I opened a boutique in London in 2019,' said Türker Bayr adding, 'I always wanted to come back to New York because my heart was always kind of here because I knew this market and this woman, but I was waiting for the right time.'
A hallmark of the brand is its chevron leather pattern which can be customized in various color and stitching details on a variety of totes, carryalls, small leather goods and even suitcases. The made-to-order styles cost the same as items in store and on the shelf.
A whipstitched leather trim also comes in 80 colors to accent the twelve base colors. Initials and the brand's Eye of the Tiger motif—a design with roots in Ottoman Empire and Eastern philosophy is a modern talisman for strength and vitality—motif can also be added to bags. Once ordered the bags which are made in Turkey, take 15 to 20 days to be created and delivered. Average price points range from $880 for an Edna tote in Anatolia print to the Sienna doctor's bag style in Los Angeles laser cut pattern for $1,300. Türker Bayr promises a special design for New York.
'I'm a textile designer, originally and I wanted to create this fabric to create timeless handbags. I played around with some designs and I created a zig zag within a Chevron,' she explained.
The Belgravia taxi cab yellow style is unique to New York.
The brand also features soft leather styles such as quilted styles and laser cut styles that recall architecture motifs. 'There's always a source of inspiration. For example, this I call Theia print which is an alternating diamond pattern,' she explained.
Since opening the store in the UK, Misela has leaned into digital marketing which helped build a US customer base, currently focused on New York and Los Angeles. Meanwhile back at home base, the brand opened a new headquarters in Istanbul, a four-story building with two floors dedicated to selling. A design atelier and headquarters occupy the other two floors.
'We partner with galleries for creative approaches in seasonal room concepts. These have been so loved so we wanted to do the same idea here in New York,' Türker Bayr added.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

LS&Co appoints Callieri to lead global supply chain operations for Levi's
LS&Co appoints Callieri to lead global supply chain operations for Levi's

Yahoo

time2 hours ago

  • Yahoo

LS&Co appoints Callieri to lead global supply chain operations for Levi's

Levi Strauss & Co (LS&Co) has appointed Chris Callieri as its senior vice-president and chief supply chain officer, as the company aims to 'evolve into a direct-to-consumer (DTC)-first denim lifestyle company'. The appointment will be effective from 15 September 2025. Callieri will report to president and CEO Michelle Gass. He will take charge of the global supply chain operations for the Levi's brand, including product development, sourcing, sustainability and logistics. Gass stated: 'We're excited to welcome Chris to LS&Co at this pivotal moment in our evolution into a DTC-first denim lifestyle company. "With a proven track record of delivering results at scale, he's the right leader to strengthen our end-to-end supply chain agility, drive innovation and advance our sustainability goals — all while delivering exceptional value to our fans worldwide." Callieri has more than two decades of international supply chain experience in the retail and consumer goods sectors. His previous position at Victoria's Secret saw him lead global teams and manage a wide range of categories, from undergarments to beauty products. Before his tenure at Victoria's Secret, Callieri made contributions to Tory Burch, where he was crucial in implementing key systems and establishing the company's sustainability strategy. His earlier roles at Adidas and in senior positions at HRC Advisory and AT Kearney involved transformational initiatives and developing strategies to enhance supply chain efficiency and product innovation. Callieri stated: 'I'm thrilled to join LS&Co at such an exciting time for the iconic Levi's brand, a true category leader that thrives at the centre of culture. "I look forward to working with the talented LS&Co team to deliver strong performance, serve our fans around the world, and strengthen Levi's position as the world's definitive denim lifestyle brand." Levi Strauss & Co owns the Levi's, Levi Strauss Signature and Beyond Yoga brands, operating in 120 countries. Its global presence includes chain retailers, department stores, online platforms and a network of 3,400 retail stores and shop-in-shops. In the first quarter of 2025, the company saw a 3% increase in net revenues to $1.53bn with net income from continuing operations of $140m. "LS&Co appoints Callieri to lead global supply chain operations for Levi's" was originally created and published by Retail Insight Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Covalon Technologies Ltd. Achieves DTC Eligibility in the United States
Covalon Technologies Ltd. Achieves DTC Eligibility in the United States

Yahoo

time4 hours ago

  • Yahoo

Covalon Technologies Ltd. Achieves DTC Eligibility in the United States

Improving Access for U.S. Investors and Supporting Share Price Appreciation for Canadian MedTech Innovator MISSISSAUGA, Ontario, August 20, 2025--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, is pleased to announce that its common shares are now eligible for electronic clearing and settlement in the United States through The Depository Trust Company ("DTC"). DTC eligibility simplifies the trading process for Covalon shares on the U.S. OTCQX Market under the symbol CVALF by eliminating manual delays and higher transaction costs often associated with cross-border securities. Most United States-based brokerage firms do not allow their customers to trade shares unless they are DTC eligible. This accomplishment will enable Covalon to generate increased U.S. interest, which will enhance liquidity and improve Covalon's positioning in the United States, where companies with Covalon's financial performance trade at much higher market values. "This is a major milestone for Covalon as we expand our visibility and access to a broader investor base," said Brent Ashton, CEO of Covalon. "Receiving DTC eligibility significantly streamlines the investment process for U.S. shareholders and demonstrates the commitment to growing our presence in U.S. capital markets, where we have received very positive feedback from investors." In addition, in the Company's May 15, 2025 press release, Covalon announced the promotion of Kim Crooks appointment to Covalon's Board of Directors, and the awarding of 150,000 common share stock options, both of which were subject to the approval of the TSX Venture Exchange. The Options were granted pursuant to the Company's Omnibus Long-Term Incentive Plan on May 30, 2025, and are subject to the terms of the applicable grant agreement, the requirements of the TSX Venture Exchange, and shareholder approval at the Company's next Annual General Meeting, scheduled in early 2026. The Options were granted at an exercise price of $2.50 per share, effective May 30, 2025. The options vest 34% on the first anniversary of the grant date, 33% on the second anniversary, and the remaining 33% on the third anniversary. The Options shall expire five (5) years from the initial grant date. Those interested in learning about Covalon's solutions may visit or follow Covalon on LinkedIn, Facebook, Instagram, or X. About CovalonCovalon is a leading medical device company dedicated to improving patient outcomes through innovative and compassionate medical products and technologies. Our expertise spans advanced wound care, vascular access, and surgical consumables, with a strong focus on enhancing healing, reducing healthcare-associated infections (HAIs), and protecting skin integrity. Our solutions are designed for patients and made for care providers. The Company is listed on the TSX Venture Exchange (COV) and trades on the OTCQX Market (CVALF). To learn more about Covalon, visit our website at Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan", "estimate", "expect", "intend", or variations of such words and phrases or state that certain actions, events, or results "may", "could", "would", "might", "will" or "will be taken", "occur", or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management's expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the "Risks and Uncertainties" section of our management's discussion and analysis of financial condition and results of operations for the year ended September 30, 2024, which is available on the Company's profile at any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law. View source version on Contacts Investor Relations, Covalon Technologies investors@ Website: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Covalon Technologies Ltd. Achieves DTC Eligibility in the United States
Covalon Technologies Ltd. Achieves DTC Eligibility in the United States

Business Wire

time5 hours ago

  • Business Wire

Covalon Technologies Ltd. Achieves DTC Eligibility in the United States

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, is pleased to announce that its common shares are now eligible for electronic clearing and settlement in the United States through The Depository Trust Company ('DTC'). DTC eligibility simplifies the trading process for Covalon shares on the U.S. OTCQX Market under the symbol CVALF by eliminating manual delays and higher transaction costs often associated with cross-border securities. Most United States-based brokerage firms do not allow their customers to trade shares unless they are DTC eligible. This accomplishment will enable Covalon to generate increased U.S. interest, which will enhance liquidity and improve Covalon's positioning in the United States, where companies with Covalon's financial performance trade at much higher market values. ' This is a major milestone for Covalon as we expand our visibility and access to a broader investor base, ' said Brent Ashton, CEO of Covalon. ' Receiving DTC eligibility significantly streamlines the investment process for U.S. shareholders and demonstrates the commitment to growing our presence in U.S. capital markets, where we have received very positive feedback from investors.' In addition, in the Company's May 15, 2025 press release, Covalon announced the promotion of Kim Crooks appointment to Covalon's Board of Directors, and the awarding of 150,000 common share stock options, both of which were subject to the approval of the TSX Venture Exchange. The Options were granted pursuant to the Company's Omnibus Long-Term Incentive Plan on May 30, 2025, and are subject to the terms of the applicable grant agreement, the requirements of the TSX Venture Exchange, and shareholder approval at the Company's next Annual General Meeting, scheduled in early 2026. The Options were granted at an exercise price of $2.50 per share, effective May 30, 2025. The options vest 34% on the first anniversary of the grant date, 33% on the second anniversary, and the remaining 33% on the third anniversary. The Options shall expire five (5) years from the initial grant date. Those interested in learning about Covalon's solutions may visit or follow Covalon on LinkedIn, Facebook, Instagram, or X. About Covalon Covalon is a leading medical device company dedicated to improving patient outcomes through innovative and compassionate medical products and technologies. Our expertise spans advanced wound care, vascular access, and surgical consumables, with a strong focus on enhancing healing, reducing healthcare-associated infections (HAIs), and protecting skin integrity. Our solutions are designed for patients and made for care providers. The Company is listed on the TSX Venture Exchange (COV) and trades on the OTCQX Market (CVALF). To learn more about Covalon, visit our website at Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as 'seek', 'anticipate', 'plan', 'estimate', 'expect', 'intend', or variations of such words and phrases or state that certain actions, events, or results 'may', 'could', 'would', 'might', 'will' or 'will be taken', 'occur', or 'be achieved'. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management's expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the 'Risks and Uncertainties' section of our management's discussion and analysis of financial condition and results of operations for the year ended September 30, 2024, which is available on the Company's profile at any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store